<DOC>
	<DOCNO>NCT00038103</DOCNO>
	<brief_summary>This open-label , multicenter , randomize ( 1:1 randomization ratio ) study either exemestane exemestane plus celecoxib postmenopausal woman ABC progress tamoxifen .</brief_summary>
	<brief_title>Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Postmenopausal female patient histologically cytologically confirm breast cancer progress Tamoxifen . Advanced disease : patient advance breast carcinoma disease progression progressed/relapsed follow &gt; 8 week treatment Tamoxifen advance disease ; progress adjuvant Tamoxifen least 6 12 month depend receptor status ; progress within 12 month completion adjuvant treatment Tamoxifen . least one measurable lesion More one previous chemotherapy and/or one hormonotherapy advance disease . Previous hormonotherapy advance disease Tamoxifen . Myocardial infarction within previous 6 mo</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>